Navigation Links
Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
Date:4/8/2008

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that a pivotal Phase 3 clinical trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, in patients following total knee replacement surgery, is underway.

In September 2007, Anesiva initiated a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the safety and efficacy of a single 5 or 15 mg dose of Adlea or placebo administered into the surgical site in patients undergoing total knee replacement surgery. Having completed enrollment of the initially planned 80 patients, Anesiva has converted this trial into a Phase 3 trial by expanding the planned enrollment by approximately 134 patients for a total sample size of 214, increasing the number of trial sites, and focusing enrollment on the 15 mg and placebo groups.

"Total knee replacement is a commonly performed orthopedic surgery that can significantly enhance patients' quality of life," said Keith Candiotti, M.D., Associate Professor of Clinical Anesthesiology and Internal Medicine; Director of Clinical Research, Chief, Division of Perioperative Medicine, University of Miami Leonard M. Miller School of Medicine, and investigator in the Phase 3 study. "The effective management of post-surgical pain is critical since patients must begin walking and moving the knee soon after the procedure in order to begin recovery and avoid complications. Adlea may offer additive pain relief and possibly reduce the use of other pain medications such as opioids, whose systemic side effects can interfere with the recovery process."

The primary efficacy endpoint of the Phase 3 trial is a time-weighted pain score (using a
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
2. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Defines Regulatory Pathway for Adlea with FDA
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... Oct. 30, 2014  Electronic health records uptake ... result of government initiatives and the considerable resources ... have invested over the past five years. Electronic ... IT, and U.S. clinicians use them on a ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & Sullivan,s ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... WESTON, Fla., Oct. 8 American Scientific Resources Inc. (PINK ... for the periods ending December 31, 2007 and December 31, ... www.Pinksheets.com . ... , is a leading provider of innovative next-generation, health, medical, ...
... , ALEXANDRIA, Va., Oct. 8 The Health Industry ... campaign focused on educating key audiences about the value ... of patient procedures are supported by medical products delivered ... role distributors play in supporting healthcare and making it ...
Cached Medicine Technology:American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008 2
(Date:10/30/2014)... her research group at the DFG Research Center for ... TU Dresden (CRTD) demonstrated for the first time the ... in three dimensions from mouse embryonic stem cells. Correct ... along the dorsal/ventral axis was observed., This study has ... Stem Cell Reports " on 30.10.2014 ., For many ...
(Date:10/30/2014)... 30, 2014 Timothy, InstaKNOT’s ... Beach firefighters, showing that you are never too young ... met firefighters Tracey and Carl at the 2013 Santa ... the Pompano Beach Chamber of Commerce. Tracey gave Timothy ... letting Timothy wear his real fireman’s hat, and extending ...
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... 30, 2014 Paramount Rx, a full-service ... increasing efforts to help people save money through its ... increase for prescription drugs in the new health care ... resources to bridge the relationship between consumers, businesses and ... biggest challenges people face today with medical costs is ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... Insurance Coverage Exclusions for Preexisting Conditions WASHINGTON, March ... -- a national, non-profit organization dedicated to the ... to health care through public policy reform at ... Senator Jay Rockefeller (D-WV) and Representative Joe Courtney ...
... Renaissance Laser and Vein Institute, the industry-leading ... patients. The Renaissance Laser and Vein Institute ... plastic and reconstructive surgery.In a faltering economy, many ... pricey beauty rituals to save money. Though this ...
... campaign goalFAIRFAX, Va., March 17 The newly formed ... million as part of its initial campaign goal and ... goal. This includes a recent pledge of $1 million ... high precision radiation therapy treatments for cancer and other ...
... Story" is a riveting 60-second spot depicting a biomedical ... March 17 The Foundation for Biomedical Research (FBR) ... Story." The 60-second spot introduces viewers to a ... cancer research, and is now herself battling this disease ...
... likely to be infected, study finds , , TUESDAY, March 17 ... help decrease the spread of tuberculosis in hospitals, researchers suggest. ... to air from patient rooms in a hospital in Lima, ... The study found that 35 percent of guinea pigs exposed ...
... April 19 SALT LAKE CITY, March 17 Within ... for trained IT professionals who understand healthcare. Western ... established to address workforce needs by offering relevant, accessible ... meet that need by offering a B.S. in ...
Cached Medicine News:Health News:National Patient Advocate Foundation Hails Senator Rockefeller, Representative Courtney for Introducing Preexisting Conditions Bill, Ensuring Patient Access to Health Coverage 2Health News:Renaissance Laser and Vein Clinic (laserandveinclinic.com) Provides Clients with Affordable Varicose Vein Removal Treatment 2Health News:Radiation Oncology Institute (ROI) Campaign Raises $7 Million 2Health News:Foundation for Biomedical Research Releases Groundbreaking PSA 2Health News:Western Governors University Addresses Rising Demand for Healthcare IT Professionals with B.S. in Health Informatics 2Health News:Western Governors University Addresses Rising Demand for Healthcare IT Professionals with B.S. in Health Informatics 3
... procedures are now greatly improved with Volk's ... new lens promotes precise and focused laser ... optimized for enhanced viewing and laser treatment ... design comes standard with LaserWindow for optimal ...
... Super Macula® 2.2 offers extremely high resolution ... while achieving an exceptionally wide 78° field ... choice for critical evaluation of the optic ... detailed views of the macula and disc. ...
... Volk Area Centralis® is excellent for ... and changes from macular degeneration, retinal ... diabetic retinopathy and other retinal conditions. ... treatment of these conditions providing excellent ...
... The original 130° QuadrAspheric lens has ... 1989 as the preferred wide field fundus ... provides a definite advantage over competitive wide ... displacement, and ease of use. This lens ...
Medicine Products: